Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for la...
Main Authors: | Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2014/617638 |
Similar Items
-
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
by: Cyrus V. Desouza, et al.
Published: (2010-01-01) -
Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01) -
Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
by: Chitrabhanu Ballav, et al.
Published: (2013-09-01) -
Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
by: Chitrabhanu Ballav, et al.
Published: (2013-01-01) -
New onset diabetes after transplantation in renal transplant recipients
by: Robinson, Steven John
Published: (2012)